about
Roles of d-Amino Acids on the Bioactivity of Host Defense PeptidesPossibilities and challenges for developing a successful vaccine for leishmaniasisAnti-parasitic Peptides from Arthropods and their Application in Drug TherapyRecent developments in drug discovery for leishmaniasis and human African trypanosomiasisEffect of BMAP-28 antimicrobial peptides on Leishmania major promastigote and amastigote growth: role of leishmanolysin in parasite survivalIn vitro and in vivo efficacy of ether lipid edelfosine against Leishmania spp. and SbV-resistant parasitesHigh parasitological failure rate of visceral leishmaniasis to sodium stibogluconate among HIV co-infected adults in EthiopiaComparative Fitness of a Parent Leishmania donovani Clinical Isolate and Its Experimentally Derived Paromomycin-Resistant StrainNonresponsiveness to standard treatment in cutaneous leishmaniasis: A case series from Sri LankaRepurposing of the Open Access Malaria Box for Kinetoplastid Diseases Identifies Novel Active Scaffolds against Trypanosomatids.Combined treatment of miltefosine and paromomycin delays the onset of experimental drug resistance in Leishmania infantum.IN VIVO AND IN VITRO ANTILEISHMANIAL EFFECTS OF METHANOLIC EXTRACT FROM BARK OF BURSERA APTERA.Molecular Docking and in Vitro Antileishmanial Evaluation of Chromene-2-thione Analogues.Evaluation of the Leishmanicidal Activity of Rutaceae and Lauraceae Ethanol Extracts on Golden Syrian Hamster (Mesocricetus auratus) Peritoneal Macrophages.Vector saliva in vaccines for visceral leishmaniasis: a brief encounter of high consequence?Vaccines to prevent leishmaniasis.Deficiency of Leishmania phosphoglycans influences the magnitude but does not affect the quality of secondary (memory) anti-Leishmania immunityIn vitro sensitivity of paired Leishmania (Viannia) braziliensis samples isolated before meglumine antimoniate treatment and after treatment failure or reactivation of cutaneous leishmaniasisUse of antimony in the treatment of leishmaniasis: current status and future directions.Optimal combinations of control strategies and cost-effective analysis for visceral leishmaniasis disease transmission.Village health workers in Bihar, India: an untapped resource in the struggle against kala-azarAntimony-resistant but not antimony-sensitive Leishmania donovani up-regulates host IL-10 to overexpress multidrug-resistant protein 1.Plant-derived compounds in treatment of leishmaniasis.Aspartic peptidases of human pathogenic trypanosomatids: perspectives and trends for chemotherapy.Identification and Characterization of miRNAs in Response to Leishmania donovani Infection: Delineation of Their Roles in Macrophage DysfunctionA Vaccine Therapy for Canine Visceral Leishmaniasis Promoted Significant Improvement of Clinical and Immune Status with Reduction in Parasite Burden.Use of Optical Imaging Technology in the Validation of a New, Rapid, Cost-Effective Drug Screen as Part of a Tiered In Vivo Screening Paradigm for Development of Drugs To Treat Cutaneous Leishmaniasis.Co-infection of visceral leishmaniasis and HIV-1: a surviving case in China and review of treatment strategies.VOSalophen: a vanadium complex with a stilbene derivative-induction of apoptosis, autophagy, and efficiency in experimental cutaneous leishmaniasis.Systematic review of clinical trials assessing the therapeutic efficacy of visceral leishmaniasis treatments: A first step to assess the feasibility of establishing an individual patient data sharing platform.Cytotoxic Activity of Holothuria leucospilota Extract against Leishmania infantum In Vitro.Repurposing of Human Kinase Inhibitors in Neglected Protozoan Diseases.Evaluating drug resistance in visceral leishmaniasis: the challenges.Leishmania donovani-specific 25- and 28-kDa urinary proteins activate macrophage effector functions, lymphocyte proliferation and Th1 cytokines production.Liposomal systems as carriers for bioactive compounds.The severity of cutaneous leishmaniasis before and after the earthquake in Bam, southeastern Iran.Solute carrier protein family 11 member 1 (Slc11a1) activation efficiently inhibits Leishmania donovani survival in host macrophages.Topical treatment with nanoliposomal Amphotericin B reduces early lesion growth but fails to induce cure in an experimental model of cutaneous leishmaniasis caused by Leishmania mexicana.ParaPep: a web resource for experimentally validated antiparasitic peptide sequences and their structuresZinc depletion promotes apoptosis-like death in drug-sensitive and antimony-resistance Leishmania donovani
P2860
Q26744734-06098BB0-99E5-4CD1-88BF-744E92BEF5B8Q26749758-1391A066-73E7-46E6-8FC2-B104E1EC34FCQ26768112-7F535E3F-00A4-4DEE-B4BD-5E4072375718Q27011766-E887DE6F-6567-4864-81AF-497FEE913AD3Q28478343-A9228F8C-30A5-4599-8902-CE00FC5EB39AQ28482212-31BBE64D-6B09-4234-BA84-95DC367B361BQ28539053-DFDAE2A7-BF91-43F1-BA8C-C73283F6D656Q28550306-641E0F54-A0A3-4D77-BF77-94977CF6B6AFQ30050470-2900CF99-C971-4A62-8310-F3B61C057BBEQ30487641-CF8A39CD-E12C-42FA-922E-1BED67CC2C58Q33728704-9DEC43E7-692E-42B2-A83D-A01C6DE4A49AQ33732878-8B607DC2-97ED-47F0-80A0-EB5731CC9075Q33752764-399DF71C-C6E3-41D0-BC84-563185665744Q33877775-08DEF583-BFF5-44E6-9124-E51B4E8CA417Q34019064-F88E6C0F-3510-4F70-9A45-E3E52779717EQ34511559-BB2BBB31-A896-41C7-A304-32DAC71F1787Q34776215-6A3ED463-2137-4377-99FA-327C46669A59Q35087276-2094C3E8-3CEC-4813-B44C-E298A45E5C04Q35377767-17A87596-E2B4-4258-B20C-0653C6EF0564Q36286410-B604CCC7-8C5A-4BE5-85B3-3C23EC9F5E59Q36557152-E38E20EF-E5E8-4FCF-BF74-33687C354161Q36616938-75BC9DD1-C3E7-4EAF-9ABF-7DAA7177828DQ36680343-024E2098-DAB3-4B94-8946-5B5C4817A2B8Q37334816-EE79AF6C-515D-4947-A7FD-9FEB11D682E5Q37675397-B70394C6-670D-4FD0-B242-20E982E86EF5Q37681950-FBAA6AF9-8154-4BD6-8671-2B4954C0B9B1Q37720821-B9362C47-A764-4E7F-A2E0-010B82700BB6Q38514270-E40A6981-9FA8-4601-AD47-AAABBB24C627Q38735051-C9449AEF-CEC0-4232-B7E2-784E2F6DB876Q38926936-48E689DA-3C90-458C-9767-C999143076BEQ38956306-CC791869-7C52-4027-9FC7-E97B87EF4763Q38972808-88139180-67DA-4B90-A2BD-57DD79559785Q39014583-FD0D8838-3262-4F2B-90AD-F7923D2F271EQ39207671-68FC0506-0DB0-4F16-BEBE-C002F1121C0DQ39310641-BCED6002-8719-4871-A48F-9A840BB85327Q39452275-47F49BF1-A88C-468B-A5E6-B7AB15B07B0CQ40076960-41550CC3-2A44-44B5-9E78-00B076EEBE93Q40177258-D019BC31-81D6-4F8B-BA19-583E9FF7B471Q40614393-F8643ECB-0DC6-471D-AE03-C17AEC1E8978Q41620343-8AF7F1F3-3FE6-49F2-A852-F919E8D38B12
P2860
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Drug resistance in leishmaniasis.
@en
type
label
Drug resistance in leishmaniasis.
@en
prefLabel
Drug resistance in leishmaniasis.
@en
P2860
P356
P1476
Drug resistance in leishmaniasis.
@en
P2093
Jaya Chakravarty
P2860
P304
P356
10.4103/0974-777X.62887
P407
P50
P577
2010-05-01T00:00:00Z